Holding(s) in Company
05/04/2023 11:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230405:nRSE4754Va&default-theme=true
RNS Number : 4754V Mediclinic International plc 05 April 2023
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")
5 April 2023
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00B8HX8Z88
Issuer Name
MEDICLINIC INTERNATIONAL PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of financial instruments
3. Details of person subject to the notification obligation
Name
The Goldman Sachs Group, Inc.
City of registered office (if applicable)
Wilmington, Delaware
Country of registered office (if applicable)
USA
4. Details of the shareholder
Name City of registered office Country of registered office
Goldman Sachs International London United Kingdom
5. Date on which the threshold was crossed or reached
31-Mar-2023
6. Date on which Issuer notified
04-Apr-2023
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached 1.074447 3.974818 5.049265 37225409
Position of previous notification (if applicable) 1.086378 4.001370 5.087748
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1)
GB00B8HX8Z88 7921295 1.074447
Sub Total 8.A 7921295 1.074447%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is % of voting rights
exercised/converted
Securities Lending Open 10182014 1.381092
Swap 15-June-2023 8997334 1.220401
Sub Total 8.B1 19179348 2.601493%
8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))
Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights
Swap 23-May-2023 Cash 8680444 1.177418
Swap 17-Aug-2026 Cash 384361 0.052135
Swap 08-Mar-2033 Cash 259311 0.035173
Swap 30-Mar-2033 Cash 185482 0.025159
Swap 17-Aug-2026 Cash 132285 0.017943
Swap 05-Jan-2033 Cash 106211 0.014406
Swap 17-Aug-2026 Cash 92303 0.012520
Swap 15-Jul-2031 Cash 89654 0.012161
Swap 17-Aug-2026 Cash 45724 0.006202
Swap 17-Aug-2026 Cash 42134 0.005715
Swap 17-Aug-2026 Cash 36389 0.004936
Swap 17-Aug-2026 Cash 19183 0.002602
Swap 17-Aug-2026 Cash 12608 0.001710
Swap 17-Aug-2026 Cash 12160 0.001649
Swap 20-Oct-2032 Cash 8893 0.001206
Swap 17-Aug-2026 Cash 5939 0.000806
Swap 17-Aug-2026 Cash 3974 0.000539
Swap 17-Aug-2026 Cash 3606 0.000489
Swap 28-Jul-2032 Cash 1915 0.000260
Swap 11-Oct-2023 Cash 1381 0.000187
Swap 17-Aug-2026 Cash 756 0.000102
Swap 30-May-2023 Cash 37 0.000005
Swap 09-May-2023 Cash 16 0.000002
Sub Total 8.B2 10124766 1.373325%
9. Information in relation to the person subject to the notification
obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add additional
rows as necessary)
Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher Total of both if it equals or is higher than the notifiable threshold
than the notifiable threshold
The Goldman Sachs Group, Inc. (Chain 1)
The Goldman Sachs Group, Inc. (Chain 1) Goldman Sachs (UK) L.L.C. 1.063875 3.974616 5.038491%
The Goldman Sachs Group, Inc. (Chain 1) Goldman Sachs Group UK Limited 1.063875 3.974616 5.038491%
The Goldman Sachs Group, Inc. (Chain 1) Goldman Sachs International 1.063875 3.974616 5.038491%
The Goldman Sachs Group, Inc. (Chain 2)
The Goldman Sachs Group, Inc. (Chain 2) GSAM Holdings LLC
The Goldman Sachs Group, Inc. (Chain 2) Goldman Sachs Asset Management, L.P.
The Goldman Sachs Group, Inc. (Chain 3)
The Goldman Sachs Group, Inc. (Chain 3) Goldman Sachs Bank USA
The Goldman Sachs Group, Inc. (Chain 3) Goldman Sachs Bank Europe SE
The Goldman Sachs Group, Inc. (Chain 4)
The Goldman Sachs Group, Inc. (Chain 4) Goldman Sachs & Co. LLC
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Please note, the total amount of voting rights have been rounded to 6 decimal
places therefore there is a possibility of a rounding error.
General email contact:
gs-regops-emea-position-enquiries@gs.com
(mailto:gs-regops-emea-position-enquiries@gs.com)
12. Date of Completion
04-Apr-2023
13. Place Of Completion
Warsaw
ABOUT MEDICLINIC INTERNATIONAL PLC
Mediclinic is a diversified international private healthcare services group,
established in South Africa in 1983, with divisions in Switzerland, Southern
Africa (South Africa and Namibia) and the Middle East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their
healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary
services across the continuum of care in such a way that the Group will be
regarded as the most respected and trusted provider of healthcare services by
patients, medical practitioners, funders and regulators of healthcare in each
of its markets.
At 31 December 2022, Mediclinic comprised 74 hospitals, five subacute
hospitals, three mental health facilities, 21 day case clinics and 23
outpatient clinics. The Swiss operations included 17 hospitals and five day
case clinics with around 1 900 inpatient beds; Southern Africa operations
included 50 hospitals (three of which in Namibia), five subacute hospitals,
three mental health facilities and 14 day case clinics (four of which operated
by Intercare) across South Africa, and around 8 750 inpatient beds; and the
Middle East operated seven hospitals, two day case clinics and 23 outpatient
clinics with around 1000 inpatient beds in the UAE. In addition, under
management contract the Middle East will open a 200-bed hospital in the
Kingdom of Saudi Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ("LSE") in the
United Kingdom, with secondary listings on the JSE in South Africa and the
Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a
leading private healthcare group based in the United Kingdom and listed on the
LSE.
CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com (mailto:ir@mediclinic.com)
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United
Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS
Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank
Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END HOLUVOKROSUSRRR